文献速递胸部肿瘤消化系统肿瘤

PD-1阻断治疗中个体病灶层面的应答动态

Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade.
PubMed 文献 · J Clin Oncol · 2019-11-01

该研究评估了转移性非小细胞肺癌(NSCLC)和错配修复缺陷(MMRD)癌患者接受PD-1单药治疗时,每个目标病灶的应答动态。结果显示,在应答患者中,个体病灶的应答时间趋于同步,且更深应答与更长的无进展生存和总生存相关;而进展时混合进展常见,且与改善的生存相关。淋巴结转移应答最高,肝转移应答最低。

要点

  • 应答患者中多数病灶同步缩小,支持外周克隆性抗肿瘤免疫的作用。
  • 进展时混合进展常见,且与较系统进展更好的生存相关。
  • 不同器官转移灶应答存在差异,淋巴结最敏感,肝转移最不敏感。

核心结论

  • 个体转移灶的应答时空模式趋于一致,支持外周克隆性抗肿瘤免疫是PD-1阻断应答的关键介质。
  • 进展模式更具异质性,可能揭示局部特征和肿瘤间异质性的临床重要性。

研究设计与样本

  • 回顾性评估接受PD-1单药治疗的转移性NSCLC或MMRD癌患者,使用RECIST量化每个目标病灶的绝对和百分比变化。
  • 共分析214例NSCLC患者的761个病灶和78例MMRD癌患者的290个病灶。

主要发现

  • 在部分缓解/完全缓解的患者中,85%的NSCLC病灶和93%的MMRD病灶应答与患者最佳总体应答一致。
  • 应答患者中,73%的NSCLC病灶和76%的MMRD病灶同步应答。
  • 更深应答与更长的无进展生存和总生存相关。
  • 淋巴结转移应答最高,肝转移应答最低。

关键数值与推荐

  • RECIST用于量化每个目标病灶的变化。
  • 进展模式预定义为系统进展或混合进展。

临床怎么用

  • 临床评估PD-1阻断疗效时,应关注个体病灶的应答动态,混合进展患者可能仍有生存获益。
  • 不同器官转移灶的应答差异提示需结合部位特征解读疗效。

局限性

  • 研究为回顾性分析,样本来自两个独立的队列。
  • 未报告其他潜在混杂因素的控制情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Response to programmed cell death protein 1 (PD-1) blockade is often conceptualized as resulting from reinvigoration of tumor-infiltrating lymphocytes. However, recruited antitumor immunity from the periphery may also be an important contributor to response. A detailed assessment of the response dynamics of individual metastasis could provide insight to the systemic and local features that mediate response and resistance to immunotherapy. MATERIALS AND METHODS: Patients with metastatic non-small-cell lung cancer (NSCLC) or mismatch repair deficiency (MMRD) carcinoma treated with PD-1 monotherapy were evaluated independently. Absolute and percent change of each target lesion were quantified at each computed tomography scan using RECIST. Patterns of progression were predefined as systemic or mixed and were correlated with clinical outcomes. RESULTS: A total of 761 individual lesions from 214 patients with NSCLC and 290 lesions from 78 patients with MMRD carcinoma were examined. Individual target lesion responses aligned with best overall response of each patient (85% NSCLC and 93% MMRD lesions responded in patients with partial response/complete response). In responding patients, timing of response was uniform (73% NSCLC and 76% MMRD lesions responded synchronously), and deeper responses were associated with prolonged progression-free survival and overall survival. By contrast, at progression, mixed progression was common (45% of NSCLC and 53% of MMRD) and associated with improved survival compared with those who experienced systemic progression (NSCLC hazard ratio [HR], 0.58; P = .001; MMRD HR, 0.40; P = .07). Organ sites had differential responses, with lymph node and liver metastasis among the most and least responsive, respectively. CONCLUSION: Temporal-spatial patterns of response across individual metastases tend to be uniform, favoring the role of peripheral, clonally directed antitumor immunity as a key mediator of response to PD-1 blockade. In contrast, progression is more heterogeneous, potentially revealing the clinical importance of local features and intertumoral heterogeneity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Osorio JC, Arbour KC, Le DT, et al. Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. J Clin Oncol. 2019. PMID: 31675272. doi:10.1200/JCO.19.00709

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。